MarginsXMarginsX
Home › Markets › Health Care › CAPR

Capricor Therapeutics Inc. (CAPR)

CAPR trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$8.30
-12.91% on the day
Market cap
$482.6M
Small cap
Revenue · 2025
$0
-100.0% on 2024
Net income · 2025
-$105.0M

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1133869/000110465926029580/0001104659-26-029580-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerCAPR on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001133869
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$0
Net income-$105.0M
Operating income-$108.1M
Net marginNeeds revenue and net income
Operating marginOperating income not reported
Revenue growth-100.0%
Cash$287.8M
Total assets$355.9M
P/E (computed)Net income was not positive
P/S (computed)Needs market cap and revenue

Warning signs

Cash runway
4.4 months
$44.3M cash at September 30, 2026
Share count, 1 year
+27.2%
2025-11-07 to 2026-11-09 · +88.8% over 3 years
Going-concern doubt
No
10-Q filed November 10, 2026
Insider net buying, 12 months
-$6.8M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-10
Cash and burn$44.3M cash; operating cash flow -$30.0M a quarter.Report 2026-09-30
Shares outstanding58,142,114 (2026-11-09); 45,718,475 a year earlier; 30,792,869 three years earlier.Cover page 2026-11-09
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the marketLatest 2025-12-05
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorRose, Snyder & Jacobs LLP, Encino, California, United StatesPCAOB Form AP 2026-03-18
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $6.8M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$42.7M-$35.7M$44.3MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q2 2026
2026-06-30
Not filed-$40.7M-$31.5M$20.9MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q1 2026
2026-03-31
Not filed-$33.9M-$29.3M$105.4MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q4 2025
2025-12-31
Not filed-$30.2M-$23.6M$287.8MNo debt tags$010-K 2026-03-17
Q3 2025
2025-09-30
Not filed-$24.6M-$19.7M$19.5MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q2 2025
2025-06-30
Not filed-$25.9M-$20.1M$23.2MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q1 2025
2025-03-31
Not filed-$24.4M-$6.4M$28.8MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q4 2024
2024-12-31
$11.1M-$7.1M-$14.8M$11.3MNo debt tags$22.3M10-K 2026-03-17

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52025-12-05
Latest annual report10-K2026-03-17
Latest quarterly / interim10-Q2026-11-10
Latest current report8-K2026-11-10
Latest proxyDEF 14A2026-04-10

Source: SEC EDGAR submissions feed, 967 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+5.9%
1 month+38.5%
3 months+126.4%
Year to date-67.0%
1 year+65.2%
From 52-week high-73.0%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
NGNENeurogene Inc. Common Stock$23.30-2.63%$482.3M
PHATPhathom Pharmaceuticals Inc.$5.88-2.97%$478.0M
MNPRMonopar Therapeutics Inc.$71.97-0.04%$487.7M
STTKShattuck Labs Inc.$4.66+0.21%$474.6M
AQSTAquestive Therapeutics Inc.$3.76-3.84%$472.6M
OCSOculis Holding AG$7.63-0.13%$469.9M
LYELLyell Immunopharma Inc.$14.65+2.45%$469.0M
KMDAKamada Ltd.$8.11+0.25%$468.0M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier